



Selecta Biosciences Announces New Employment Inducement Grant

Watertown, Mass., March 26, 2019 – Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Elona Kogan, J.D. commenced her services as the company's General Counsel and Corporate Secretary. In connection with the commencement of Ms. Kogan's services, the company issued to Ms. Kogan an option to purchase an aggregate of 400,000 shares of the company's common stock with a per share exercise price of \$2.29, the closing trading price of the company's common stock on the Nasdaq Global Market on March 25, 2019, and 100,000 performance-based restricted stock units. The option and the restricted stock units were granted pursuant to the company's 2018 Employment Inducement Incentive Award Plan and were approved by the company's board of directors. The option vests 25% on March 20, 2020 and in 36 substantially equal monthly installments over the three years thereafter and has a ten-year term. The restricted stock units vest upon the achievement of specified performance goals. The stock option and restricted stock units were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as inducement material to Ms. Kogan's entering into employment with the company.

About Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company's current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates. SEL-212, the company's lead product candidate, is being developed to treat chronic refractory gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's proprietary gene therapy product candidates are in preclinical development for certain rare inborn errors of metabolism and incorporate ImmTOR with the goal of addressing barriers to repeat administration. Selecta is based in Watertown, Massachusetts. For more information, please visit <http://selectabio.com>.

Forward-Looking Statements

Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the ability of the company's ImmTOR platform, including SEL-212, to unlock the full potential of biologic therapies, the potential of SEL-212 to treat chronic refractory gout patients and resolve their debilitating symptoms, the potential treatment applications for product candidates utilizing the ImmTOR platform in areas such as enzyme therapy and gene therapy, the company's plan to apply its ImmTOR technology platform to a range of biologics for rare and serious diseases, the potential of the company's two gene therapy product candidates to enable repeat administration, the potential of the ImmTOR technology platform generally, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "hypothesize," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of



the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the unproven approach of the company's SVP technology, potential delays in enrollment of patients, undesirable side effects of the company's product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company's inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, substantial fluctuation in the price of its common stock, and other important factors discussed in the "Risk Factors" section of the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 15, 2019, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.

###

Investors:

Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah@sternir.com

Media:

Lauren Tortorete
Spectrum Science Communications, Inc.
+1-212-468-5379
ltortorete@spectrumscience.com